Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry

Journal of Molecular Neuroscience

Volumn 31, Issue 3, 2007, Pages 183-200

  Hill, Joanna M ^a   Hauser, Janet M ^a   Sheppard, Lia M ^a   Abebe, Daniel ^a   Spivak Pohis, Irit ^b   Kushnir, Michal ^b   Deitch, Iris ^b   Gozes, Illana ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Activity dependent neuroprotective protein (ADNP); Anxiety like behavior; Autism; Neurodevelopmental disorders; Neuronal survival; Social behavior; Synaptogenesis

Indexed keywords

VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTIBODY; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASTROCYTE; BEHAVIOR MODIFICATION; BRAIN LEVEL; BRAIN TISSUE; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; EMBRYO DEVELOPMENT; FEMALE; GENE EXPRESSION; GLIA CELL; MALE; MOUSE; NERVE CELL; NEWBORN; NONHUMAN; PROGENY; PROTEIN BINDING; RECOGNITION; SOCIAL BEHAVIOR; STATISTICAL SIGNIFICANCE;

ANIMALS; ASTROCYTES; BEHAVIOR, ANIMAL; BRAIN; BRAIN CHEMISTRY; CELLS, CULTURED; CHOLINE O-ACETYLTRANSFERASE; EMBRYONIC DEVELOPMENT; FEMALE; HOMEODOMAIN PROTEINS; MALE; MICE; NERVE TISSUE PROTEINS; NEURONS; PREGNANCY; SOCIAL BEHAVIOR; SYNAPTOPHYSIN; VASOACTIVE INTESTINAL PEPTIDE;

ANIMALIA; MUS; RODENTIA;

EID: 34548320851     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (108)

1. Alcalay R. N., Giladi E., Pick C. G., and Gozes I. (2004) Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci. Lett. 361, 128-131.
2. Bailey A., Luthert P., Dean A., Harding B., Janota I., Montgomery M., Rutter M., and Lantos P. (1998) A clinicopathological study of autism. Brain 121, 889-905.
3. Baker J., Liu J-P., Robertson E. J., and Efstratiadis A. (1993) Role of insulin like growth factors in embryonic and postnatal growth. Cell 75, 73-82.
4. Baron-Cohen S., Ring H. A., Bullmore E. T., Wheelright S., Ashwin C., and Williams S. C. (2000) The amygdala theory of autism. Neurosci. Biobehav. Rev. 24, 355-364.
5. Bassan M., Zamostiano R., Davidson A., et al. (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 72, 1283-1293.
6. Berry J. F. and Whittaker V. P. (1959) The acyl-group specificity of choline acetylase. Biochem. J. 73, 447-458.
7. Bielsky I. F., Hu S. B., Szegda K. L., Westphal H., and Young L. J. (2004) Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacol. 29, 483-493.
8. Brennemen D. E. and Gozes I. (1996) A femtomolar-acting neuroprotective peptide. J. Clin. Invest . 97, 2299-2307.
9. Brenneman D. E., Hauser J., Mokolla M., et al. (2001) VIP-mediated regulation of chemokine, cytokine and growth factor release from glial cultures derived from a mouse model of mental retardation. Regul. Pept. 102, 51.
10. Brenneman D. E., Hauser J., Spong C. Y., and Phillips T. W. (1999) VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death. Brain Res. 838, 27-36.
11. Brenneman D. E., Hill J. M., Glazner G. W., Gozes I., and Phillips T. W. (1995) Interleukin-1 alpha and vasoactive intestinal peptide: enigmatic regulation of neuronal survival. J. Dev. Neurosci. 13, 187-200.
12. Brennemen D. E., Hill J. M., and Gozes I. (in press) VIP/PACAPand Receptors. New Encyclopedia of Neuroscience. (Larry Squire, Tom Albright, Floyd Bloom, Fred Gage, and Nick Spitzer, eds.), Elsevier.
13. Brenneman D. E., Neale E. A., Foster G. A., d'Autremont S. W., and Westbrook G. L. (1987) Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide. J. Cell Biol. 104, 1603-1610.
14. Brenneman D. E., Nicol T., Warren D., and Bowers L. M. (1990) Vasoactive intestinal peptide: a neurotrophic releasing agent and an astroglial mitogen. J. Neurosci. Res. 25, 386-394.
15. Busciglio J., Pelsman A., Helguera P., et al. (2007) NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. Curr. Pharmaceut. Design, in press.
16. Chen S. Y., Charness M. E., Wilkemeyer M. F., and Sulik K. K. (2005) Peptide-mediated protection from ethanol-induced neural tube defects. Dev. Neurosci. 27, 13-19.
17. Christianson A. L., Chesler N., and Kromberg J. G. R. (1994) Fetal valproate syndrome - clinical and neurodevelopmental features in two sibling pairs. Dev. Med. Child. Neurol. 36, 357-369.
18. Colwell C. S., Michel S., Itri J., et al. (2003) Disrupted circadian rhythms in VIP- and PHI-deficient mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 258, R939-R949.
19. Dangoor D., Giladi E., Fridkin M., and Gozes I. (2005) Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina. Peptides 26, 2579-2584.
20. Davidson A., Moody T.W., and Gozes I. (1996) Regulation of VIP gene expression in general. Human lung cancer cells in particular. J. Mol. Neurosci. 7, 99-110.
21. Delgado M., Pozo D., and Ganea D. (2004) The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 56, 249-290.
22. Demas G. E., Nelson R. J., Krueger B. K., and Yarowsky P. J. (1998) Impaired spatial working and reference memory in segmental trisomy (Ts65Dn) mice. Behav. Brain Res. 90, 199-201.
23. Elia M., Ferri R., Musumeci S., et al. (2000) Sleep in subjects with autistic disorder: a neurophysiological and psychological study. Brain Dev. 22, 88-92.
24. Escorihuela R. M., Fernandez-Teruel A., Vallina I. F., et al. (1995) A behavioral assessment of Ts65Dn mice: A putative Down syndrome model. Neurosci. Lett. 99, 143-146.
25. Ferguson J. N., Young L. J., Hearn E. F., Matzuk M. M., Insel T. R., and Winslow J. T. (2000) Social amnesia in mice lacking the oxytocin gene. Nat. Genet. 25, 284-288.
26. Fonnum F. (1966) A radiochemical method for the estimation of choline acetyltransferase. Biochem. J. 100, 479-484.
27. Fombonne E. (1998) Inflammatory bower disease and autism. The Lancet 351, 955.
28. Franklin K. B. and Paxinos G. (2001) The Mouse Brain in Stereotaxic Coordinates. Academic Press, NY.
29. Furman S., Hill J. M., Vulih I., et al.. (2005) Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neurosci. Lett. 373, 73-78.
30. Furman S., Steingart R. A., Mandel S., Hauser J. M., Brenneman D. E., and Gozes I. (2004) Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol. 1, 193-199.
31. Gaffney G. R., Tsai L. Y., Kuperman S., and Minchin S. (1987) Cerebellar structure in autism. Am. J. Dis. Child. 141, 1330-1332.
32. Glazner G. W., Gressens P., Lee S. J., et al. (1999) Activity-dependent neurotrophic factor: A potent regulator of embryonic growth. Anat. Embryol. 200, 65-71.
33. Glowa J. R., Panlilio L. V., Brenneman D. E., Gozes I., Fridkin M., and Hill J. M. (1992) Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res. 570, 49-53.
34. Gozes I. and Furman S. (2004) Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update. Best Pract. Res. Clin. Endocrinol. Metab. 18, 623-640.
35. Gozes I., Bachar M., Bardea A., et al. (1997) Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. J. Neurobiol. 33, 329-342.
36. Gozes I., Glowa J., Brenneman D. E., McCune S. K., Lee E., and Westphal H. (1993) Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene. J. Mol. Neurosci. 4, 185-193.
37. Gozes I., Lilling G., Glazer R., et al. (1995) Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J. Pharmacol. Exp. Ther. 273, 161-167.
38. Gozes I., McCune S. K., Jacobson L., et al. (1991) An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J. Pharmacol. Exp. Ther. 257, 959-966.
39. Gozes I., Melzer E., Rubinrout S., Brenneman D. E., and Fridkin M. (1989a) Vasoactive intestinal peptide potentiates sexual behavior: Inhibition by novel antagonist. Endocrinology 125, 2945-2949.
40. Gozes I., Morimoto B. H., Tiong J., et al. (2005a) NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev. 11, 353-368.
41. Gozes I., Schachter P., Shani Y., and Giladi E. (1988) Vasoactive intestinal peptide gene expression from embryos to aging rats. Neuroendocrinology. 47, 27-31.
42. Gozes I., Werner H., Fawzi M., et al. (1989b) Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus. J. Mol. Neurosci. 1, 55-61.
43. Gozes I., Zaltzman R., Hauser J., Brenneman D. E., Shohami E., and Hill J. M. (2005b) The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Curr. Alzheimer Res. 2, 149-153.
44. Gressens P., Hill J. M., Gozes I., Fridkin M., and Brenneman D. E. (1993) Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature 362, 155-158.
45. Gressens P., Hill J. M., Paindaveine P., Gozes I., Fridkin M., and Brenneman D. E. (1994) Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J. Clin. Invest. 94, 2020-2027.
46. Gressens P., Paindaveine B., Hill J. M., Evrard P., and Brenneman D. E. (1998) Vasoactive intestinal peptide shortens both G1 and S phases of cell cycle in whole cultured mouse embryos. Eur. J. Neurosci. 10, 1734-1742.
47. Hill J. M. (2006) Vasoactive intestinal peptide in neurodevelopmental disorders: Therapeutic potential. Curr. Pharmaceut. Design. in press.
48. Hill J. M., Ades A. M., McCune S. K., et al. (2003) Vasoactive intestinal peptide in the brain of a mouse model for Down syndrome. Exper. Neurol. 183, 56-65.
49. Hill J. M., Gozes I., Hill J. L., Fridkin M., and Brenneman D. E. (1991) Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides 12, 187-192.
50. Hill J. M., Lee S. J., Dibbern D. A., Fridkin M., Gozes I., and Brenneman D. E. (1999) Pharmacologically distinct vasoactive intestinal peptide binding sites: CNS localization and role in embryonic growth. Neurosci. 93, 783-791.
51. Hill J. M., Mehnert J., McCune S. K., and Brenneman D. E. (2002) Vasoactive intestinal peptide regulation of nerve growth factor in the embryonic mouse. Peptides 23, 1803-1808.
52. Hill J. M., Mervis, R. F., Avidor R., Moody T. W., and Brenneman D. E. (1993) HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates. Brain Res. 603, 222-233.
53. Hill J. M., Mervis R. F., Politi J., et al. (1994) Blockade of VIP during neonatal development induces neuronal damage and increases VIP and VIP receptors in brain. Ann. N. Y. Acad. Sci. 739, 211-225.
54. Holtzman D. M., Kilbridge J., Chen K. S., et al. (1995) Preliminary characterization of the central nervous system in partial trisomy 16 mice. Prog. Clin. Biol. Res. 393, 227-240.
55. Holtzman D. M., Santucci D., Kilbridge J., et al. (1996) Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 93, 13,333-13,338.
56. Holtzman R. L., Malach R., and Gozes I. (1989) Disruption of the optic pathway during development affects vasoactive intestinal peptide mRNA expression. New Biol. 1, 215-221.
57. Ingram J. L., Peckham M., Tisdale B., and Rodier P. M. (2000) Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol. Teratol. 22, 319-324.
58. Insel T. F. and Young L. J. (2000) Neuropeptides and the evolution of social behavior. Curr. Opin. Neurbiol. 1, 784-789.
59. Ishihara T., Shigemoto R., Mori K., Takahashi K., and Nagata S. (1992) Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8, 811-819.
60. Jessell T. M. and Dodd J. (1992) Floor plate-derived signals and the control of neural cell pattern in vertebrates. The Harvey Lectures Series 86, 87-128.
61. Kendrick K. M., DaCosta A. P. C., Broad K. D., et al. (1997) Neural control of maternal behavior and olfactory recognition of offspring. Brain Res. Bull. 44, 383-395.
62. Keverne E. B. and Brennen P. A. (1996) Olfactory recognition memory. J. Physiol. Paris 90, 399-401.
63. Kurt M. A., Kafa M. I., Dierssen M., and Davies D. C. (2004). Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome. Brain Res. 1022, 101-109.
64. Lee K. H., Farrow F. D., Spence S. A., and Woodruff P. W. R. (2004) Social cognition, brain networks and schizophrenia. Psycho. Med. 334, 391-400.
65. Liu J-P., Baker J., Perkins A. S., Robertson E. J., and Efstratiadis A. (1993) Mice carrying null mutations of the genes encoding insulin-like growth factor-1 (IGF-1) and type-1 IGF receptor (IGF-1R). Cell 75, 59-72.
66. Lutz E. M., Sheward W. J., West K. M., Morrow J. A., and Harmar A. J. (1993) The VIP2 receptor: molecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett. 334, 3-8.
67. Miller M. T. and Stromland K. (1993) Thalidomide embryopathy: an insight into autism? Teratol. 47, 387-388.
68. Miyazaki K., Narita N., and Narita M. (2005) Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: implication for pathogenesis of autism. Inter. J. Devel. Neurosci. 23, 287-297.
69. Moody T. W., Zia F., Draoui M., et al. (1993) A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc. Natl. Acad. Sci. U. S. A. 90, 4345-4349.
70. Nanson J. L. (1992) Autism in fetal alcohol syndrome - a report of six cases. Alcohol Clin. Exp. Res. 16, 558-565.
71. Nelson K. B., Grether J. K., Croen L. A., et al. (2001) Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann. Neurol. 49, 597-606.
72. Nicot A., Otto T., Brabet P., and DiCicco-Bloom E. M. (2004) Altered social behavior in pituitary adenylate cyclase-activating polypeptide type 1 receptor-deficient mice. J. Neurosci. 24, 8786-8795.
73. Pandey S. C., Roy A., and Zhang H. B. (2003) The decreased phosphorylation of cyclic adenosine monophosphate (cAMP) response element binding (CREB) protein in the central amygdala acts as a molecular substrate for anxiety related to ethanol withdrawal in rats. Alcohol. Clin. Exper. Res. 27, 396-409.
74. Pilzer I. and Gozes I. (2006) VIP provides cellular protection through a specific splice variant of the PACAP receptor: A new neuroprotection target. Peptides. Epub ahead of print
75. Pinhasov A., Mandel S., Torchinsky A., et al. (2003) Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res. Dev. Brain Res. 144, 83-90.
76. Pisegna J. and Wank S. A. (1993) Molecular cloning and functional expression of the pituitary adenylate cyclase activation polypeptide type 1 receptor. Proc. Natl. Acad. Sci. 90, 6345-6349.
77. Poggi S. H., Goodwin K., Hill J. M., et al. (2003) The role of activity-dependent neuroprotective protein in a mouse model of fetal alcohol syndrome. Am. J. Obstet. Gynecol. 189, 790-793.
78. Powell-Braxton L., Hollingshead P., Warburton C., et al. (1993) IGF-1 is required for normal embryonic growth in mice. Genes Develop. 7, 2609-2617.
79. Reeves R. H., Irving N. G., Moran T. H., et al. (1995) A mouse model for Down syndrome exhibits learning and behavior deficits. Nature Genet. 11, 177-184.
80. Rodier P. M., Ingram J. L., Tisdale B. and Croog V. J. (1997) Linking etiologies in humans and animal models: studies of autism. Reprod. Toxicol. 11, 417-422.
81. Rodier P. M., Ingram J. L., Tisdale B., Nelson S., and Romano J. (1996) Embryological origin for autism: developmental anomalies of the cranial nerve motor nuclei. J. Comp. Neurol. 370, 247-261.
82. Sahir N., Brenneman D. E., and Hill J. M. (in press) Neonatal mice of the Down syndrome model, Ts65Dn, exhibit upregulated VIP measures and reduced responsiveness of cortical astrocytes to VIP stimulation. J. Mol. Neurosci. 30, 329-340.
83. Schneider T. and Przewlocki R. (2005) Behavioral alterationsin rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharm. 30, 80-89.
84. Servoss S. J., Lee S. J., Gibney G., Brenneman D. E., and Hill J. M. (2001) Insulin-like growth factor-I as a mediator of vasoactive intestinal peptide/activity-dependent neurotrophic factor-stimulated embryonic growth. Endocrinology 142, 3348-3353.
85. Sigalov E., Fridkin M., Brenneman D. E., and Gozes I. (2000) VIP-related protection against iodoacetate toxicity in pheochromocytoma (PC12) cells. J. Mol. Neurosci. 15, 147-154.
86. Simon-Arceo K., Ramirex-Salado I., and Calvo J. M. (2003) Long-lasting enhancement of rapid eye movement sleep and pontogeniculooccipital waves by vasoactive intestinal peptide microinjection into the amygdala temporal lobe. Sleep 26, 259-264.
87. Spong C. Y., Abebe D. T., Gozes I., Brenneman D. E., and Hill J. M. (2001) Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. J. Pharmacol. Exp. Ther. 297, 774-779.
88. Spong C. Y., Lee S. J., McCune S. K., et al. (1999) Maternal regulation of embryonic growth: The role of vasoactive intestinal peptide. Endocrinology 140, 917-924.
89. Spong C. Y., Auth J., Vink J., et al. (2002) Vasoactive intestinal peptide mRNA and immunoreactivity are decreased in fetal alcohol syndrome model. Reg. Pept. 108, 143-147.
90. Steingart R. A. and Gozes I. (2006) Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress. Mol. Cell Endocrinol.252,148-153.
91. Stromland K., Nordin V., Miller M. T., Akerstrom B., and Gillberg C. (1994) Autism in thalidomide embryopathy - a population study. Dev. Med. Child. Neurol. 36, 351-356.
92. Taira M., Takase M., and Sasaki H. (1998) Sleep disorder in children with autism. Psychiat. Clinical Neurosci. 52, 182-183.
93. Thirumalai S. S., Shubin R. A., and Robinson R. (2002) Rapid eye movement sleep behavior disorder in children with autism. J. Child. Neurol. 17, 173-178.
94. Thor D. H. and Holloway W. R. (1982) Social memory of the male laboratory rat. J. Comp. Physiol, Psychol. 96, 1000-1006.
95. Tsai L. Y. and Ghaziuddin M. (1996) Autistic disorder. In: The Comprehensive Textbook of Child and Adolescent Psychiatry. 2nd ed. (Weiner, J. ed.). Washington (DC), American Psychiatric Press: pp. 219-254.
96. Usdin T. B., Bonner T. I., and Mezey E. (1994) Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135, 2662-2680.
97. Vertongen P., Schiffmann S. N., Gourlet P., and Robberecht P. (1997) Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Peptides 18, 1547-1554.
98. Waschek J. A., Elloison J., Bravo D. T., and Handley V. (1996) Embryonic expression of vasoactive intestinal peptide (VIP) and VIPreceptor genes. Neurochem, 66, 1762-1765.
99. Wenger G. R., Schmidt C., and Davisson M. T. (2004) Operant conditioning in the Ts65Dn mouse: Learning. Behav. Gen. 34, 105-119.
100. Werner H., Koch Y., Fridkin M., Fahrenkrug J., and Gozes I. (1985) High levels of vasoactive intestinal peptide in human milk. Biochem. Biophys. Res. Commun. 133, 228-232.
101. White D. M., Walker S., Brenneman D. E., and Gozes I. (2000). CREB contributes to the increase neurite outgrowth of sensory neurons induced by vasoactive intestinal polypeptide and activity-dependent neurotrophic factor. Brain Res. 868, 31-38.
102. Williams P. G., King J., Cunningham M., Steohan M., Kerr B., and Hersh J. H. (2001) Fetal valproate syndrome and autism: additional evidence of an association. Dev. Med. Child. Neurol. 43, 202-206.
103. Williams P. G. and Hersch J. H. (1997) A male with fetal valproate syndrome and autism. Dev. Med. Child. Neurol. 36, 632-634.
104. Williams P. G., Sears L. L., and Allard A. (2004) Sleep problems in children with autism. J. Sleep Res. 13, 265-268.
105. Wu J., Henins K. A., Gressens P., et al. (1997) Prenatal blockage of vasoactive intestinal peptide delays developmental milestones in the neonatal mouse. Peptides 18, 1131-1137.
106. Zaltzman R., Alexandrovich A., Trembovler V., Shohami E., and Gozes I. (2005) The influence of the peptide NAP on Mac-1-deficient mice following closed head injury. Peptides. 26, 1520-1527.
107. Zamostiano R., Pinhasov A., Gelber E., et al. (2001) Cloning and characterization of the human activity-dependent neuroprotective protein. J. Biol. Chem. 276, 708-714.
108. Zusev M. and Gozes I. (2004) Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regul. Pept. 123, 33-41.